Table 3.
Fold change in lipid metabolites in HFCS-exposed 6-week-old animals
| Female | q value | Male | q value | ||
|---|---|---|---|---|---|
| Essential fatty acid | Linoleate (18:2n6) | 1.13 | 0.0557 | 0.92 | 0.1779 |
| Linolenate [alpha or gamma; (18:3n3 or 6)] | 0.84 | 0.108 | 0.68 | 0.0199 | |
| Dihomo-linolenate (20:3n3 or n6) | 1.11 | 0.04 | 1.47 | 2.46E-05 | |
| Eicosapentaenoate (EPA; 20:5n3) | 0.75 | 0.0736 | 0.71 | 0.0262 | |
| Docosapentaenoate (n3 DPA; 22:5n3) | 0.36 | 1.06E-06 | 0.47 | 0.0001 | |
| Docosapentaenoate (n6 DPA; 22:5n6) | 0.36 | 6.78E-08 | 1.14 | 0.2672 | |
| Eicosanoids | 0.74 | 0.0012 | 0.86 | 0.0531 | |
| Medium chain fatty acid | Caproate (6:0) | 0.89 | 0.0658 | 1.17 | 0.0685 |
| Heptanoate (7:0) | 0.74 | 0.0212 | 0.66 | 0.0161 | |
| Caprylate (8:0) | 1.04 | 0.2307 | 0.96 | 0.3424 | |
| Pelargonate (9:0) | 1.04 | 0.1564 | 1.12 | 0.0995 | |
| Caprate (10:0) | 0.87 | 0.017 | 0.93 | 0.1224 | |
| Laurate (12:0) | 0.91 | 0.093 | 0.93 | 0.1529 | |
| Long chain fatty acid | Myristate (14:0) | 2.19 | 1.90E-07 | 1.37 | 0.0125 |
| Myristoleate (14:1n5) | 2.14 | 1.66E-06 | 1.52 | 0.0033 | |
| Palmitate (16:0) | 1.46 | 0.0002 | 1.14 | 0.1154 | |
| Palmitoleate (16:1n7) | 4.21 | 1.74E-09 | 2.31 | 0.0001 | |
| Margarate (17:0) | 0.82 | 0.0018 | 0.84 | 0.0092 | |
| 10-Heptadecenoate (17:1n7) | 2.6 | 2.89E-08 | 1.68 | 0.0006 | |
| Stearate (18:0) | 1.28 | 0.0099 | 1.16 | 0.1149 | |
| Oleate (18:1n9) | 3.24 | 2.37E-12 | 1.87 | 1.42E-06 | |
| cis-Vaccenate (18:1n7) | 3.25 | 1.33E-08 | 2.36 | 2.20E-05 | |
| stearidonate (18:4n3) | 0.55 | 0.0056 | 0.51 | 0.0044 | |
| Nonadecanoate (19:0) | 0.69 | 1.53E-05 | 0.63 | 6.44E-06 | |
| 10-Nonadecenoate (19:1n9) | 2.63 | 3.23E-09 | 1.86 | 2.59E-05 | |
| Eicosenoate (20:1n9 or 11) | 5.54 | 1.00E-15 | 2.24 | 5.29E-08 | |
| Dihomo-linoleate (20:2n6) | 1.35 | 0.0008 | 1.32 | 0.0069 | |
| Arachidonate (20:4n6) | 0.81 | 0.0011 | 0.98 | 0.2902 | |
| Erucate (22:1n9) | 1.74 | 0.0002 | 1.36 | 0.0593 | |
| Docosadienoate (22:2n6) | 1.06 | 0.1262 | 0.89 | 0.0409 | |
| Docosatrienoate (22:3n3) | 2.07 | 3.70E-05 | 4.31 | 2.71E-08 | |
| Adrenate (22:4n6) | 0.55 | 5.35E-07 | 0.69 | 0.0006 | |
| Fatty acid, monohydroxy | 3-Hydroxydecanoate | 0.93 | 0.1841 | 1.01 | 0.3337 |
| 16-Hydroxypalmitate | 0.75 | 0.001 | 1 | 0.3863 | |
| 2-Hydroxystearate | 0.58 | 0.0009 | 0.9 | 0.1836 | |
| 13-HODE + 9-HODE | 1.12 | 0.243 | 1.1 | 0.2682 | |
| Fatty acid, dicarboxylate | 2-Hydroxyglutarate | 1 | 0.2491 | 1.27 | 0.0033 |
| Hexadecanedioate | 1.14 | 0.0543 | 1.12 | 0.1015 | |
| Fatty acid, branched | 17-Methylstearate | 1.33 | 0.0014 | 0.89 | 0.0929 |
| Eicosanoid | 6-Keto prostaglandin F1alpha | 0.8 | 0.0693 | 1.47 | 0.085 |
| Endocannabinoid | Palmitoyl ethanolamide | 1.05 | 0.1627 | 1.26 | 0.0142 |
| Fatty acid metabolism (also BCAA metabolism) | Propionylcarnitine | 0.26 | 1.21E-05 | 0.81 | 0.1997 |
| Butyrylglycine | 1.59 | 0.0617 | 0.92 | 0.2977 | |
| Fatty acid metabolism | Hexanoylglycine | 1.06 | 0.1793 | 0.86 | 0.1801 |
| Carnitine metabolism | Deoxycarnitine | 0.7 | 0.0006 | 0.62 | 0.0002 |
| Carnitine | 0.85 | 0.0105 | 1.03 | 0.3307 | |
| 3-Dehydrocarnitine | 0.49 | 9.90E-08 | 0.72 | 0.0019 | |
| Acetylcarnitine | 0.66 | 0.001 | 0.99 | 0.3433 |
Significance determined by two-way ANOVA, where sex and treatment were factors and corrected for multiple testing using the FDR. N = 8 per group.